All PlansCoverageMedium impact
Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology, Pathology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has updated their policy on liquid biopsy testing (circulating tumor DNA and circulating tumor cells) for cancer management, declaring all uses investigational except those covered under separate specific policies. The policy provides detailed information about FDA-approved companion diagnostic tests but maintains that general liquid biopsy applications remain non-covered.
Action Required
Immediately: Billing team should review current liquid biopsy test billing practices and verify that any ctDNA or CTC testing claims are supported by separate specific policies (e.g., NSCLC, colorectal cancer, prostate cancer policies) rather than this general policy. Denied claims for investigational liquid biopsy tests should be expected unless covered under companion diagnostic indications listed in the FDA table.